The European Commission has authorised the marketing of the citrate-free high concentration formulation (HCF) of Hyrimoz (adalimumab) in the European Union. Hyrimoz is biosimilar to the already approved drug Humira. The approval covers all the indications treated by the reference medication (Humira), including rheumatic diseases, Crohn's disease, ulcerative colitis, plaque...
Rheumatoid arthritis: European approval for high concentration biosimilar formula
Deepa Varma | Medical News | 07 April 2023
Register or log in to read more
Registration is free and easy, giving you complete access to all Univadis content.Create a Free Account I have an account